Insider Activity: Pearce Michael Cooper Buys Shares of Journey Medical Corporation
Pearce Michael Cooper purchased 10,000 shares of Journey Medical Corporation on June 25, 2026.
Key Points
- On June 25, 2026, insider Pearce Michael Cooper bought 10,000 shares of Journey Medical Corporation.
- Shares of NasdaqCM:DERM traded near $6.22 on Saturday, with a market cap of approximately $182.3 million.
- Wasatch Advisors LP increased its stake by 817,095 shares, while Tang Capital Management LLC reduced by 244,596 shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 25, 2026, insider Pearce Michael Cooper purchased 10,000 shares of Journey Medical Corporation (NasdaqCM:DERM). This transaction was not planned under a Rule 10b5-1 trading plan.
Insider Buying and Selling at Journey Medical Corporation
In addition to Michael Cooper's purchase, other insiders were active on the same date. Justin Adam Smith and Neil Herskowitz each acquired 10,000 shares. Earlier in the year, on April 22, CFO Joseph Benesch purchased 28,907 shares, and Chief Operating Officer Ramsey Alloush bought 62,795 shares.
Other Institutional Activity in Journey Medical Corporation
Wasatch Advisors LP significantly increased its holdings by 817,095 shares, bringing its total to 2,133,370 shares valued at about $10 million. Meanwhile, Tang Capital Management LLC reduced its position by 244,596 shares, ending with 1,610,000 shares worth approximately $7.6 million. Vanguard Capital Management LLC opened a new position with 1,082,080 shares valued at around $5.1 million. BlackRock, Inc. added 253,078 shares, growing its stake by 35.2% to 972,862 shares, valued at $4.6 million. Opaleye Management Inc. slightly trimmed its holdings by 15,000 shares, maintaining 960,000 shares worth $4.5 million.
Journey Medical Corporation Stock Down 11.4%
Shares of Journey Medical Corporation traded near $6.22 on Saturday. The company has a market capitalization of approximately $182.3 million. It currently has a forward P/E ratio that isn't meaningful due to negative earnings, and a beta of 1.097. The stock's 52-week range is between $4.31 and $9.55, with a 50-day moving average of $5.79 and a 200-day moving average of $7.12. Journey Medical Corporation maintains a current ratio of 1.717 and a quick ratio of 1.38, with a debt-to-equity ratio of 82.602.
$DERM stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Journey Medical Corporation reported revenue of $64.68 million, reflecting a growth rate of 21.5%. However, the company is not currently profitable, with a net margin of -14.8% and a return on equity of -36.6%. The next earnings report is expected on August 11, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
Analyst view held steady after the report.
-
EPS & revenue
EPS missed estimates by 1.1%. Revenue missed estimates by 1.9%.
-
Profit surprise
EBITDA missed sharply. Operating income missed by 63 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
- Analyst signal
-
Earnings quality
Gross margin down 1.5 points. Operating margin up 16.0 points. Positive free cash flow.
Earnings Call Summary
Journey Medical delivered $16 million in total revenue, up 21 percent from last year, driven mainly by Emrosi which hit $6.3 million and 30,000 prescriptions. The company achieved positive adjusted EBITDA of $600,000 and ended with $27.2 million in cash. Management highlighted that Emrosi is gaining momentum with 3,700 unique prescribers, better refill ratios at 1.4 to 1, and just secured agreements with all three major group purchasing organizations covering 169 million commercial lives.
Guidance Management said they will offer detailed guidance later this year but expect the company to deliver positive adjusted EBITDA and positive EBITDA for the rest of 2026 and beyond. They expect Emrosi revenue to continue growing as payer coverage expands and prescription volumes increase.
Negative report. Results or guidance disappointed and expectations are likely to move lower.
Analysts Set New Price Targets
On March 26, 2026, HC Wainwright & Co. reiterated its 'buy' rating for Journey Medical Corporation, setting a price target of $13. The consensus among analysts is a 'strong buy' with a mean price target of $13.5, based on four analyst opinions.
About Journey Medical Corporation
Journey Medical Corporation, based in Scottsdale, Arizona, is a pharmaceutical company focused on treating dermatological conditions. Its products include Qbrexza for hyperhidrosis, Accutane for severe acne, and Amzeeq for acne vulgaris. The company also offers Zilxi and Emrosi for rosacea, Exelderm for fungal infections, and other treatments. Journey Medical was founded in 2014 and is led by CEO Mr. Claude Maraoui.
Bottom Line
The recent insider purchases at Journey Medical Corporation, including those by Pearce Michael Cooper, highlight ongoing interest in the company's stock. Investors often track insider activity for potential insights into a company's future. It's important to remember that such transactions are disclosed after they occur and may not indicate future performance.
Get Journey Medical Corporation alerts
New 13F filings, insider trades, and analyst moves on $DERM, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.